Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US1143401024
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000DX9JV7
AZTA
Azenta Inc
GICS: Information Technology · SECTOR: EQTY · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $HLTH
NAME
Azenta Inc
ISIN
US1143401024
TICKER
AZTA
MIC
XNAS
REUTERS
AZTA.OQ
BLOOMBERG
AZTA US
Tue, 04.08.2026       Azenta
US1143401024

BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026. The results of B Medical Systems are reported as discontinued operations and reflected in total diluted EPS. The Company entered into a definitive agreement to sell the business during fiscal 2025,...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Azenta
US1143401024

BURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.The Company will host a conference call and live webcast to discuss its financial results the following day, Wednesday, August 5, 2026, at 8:...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.07.2026       Azenta
US1143401024

BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.à r.l.The transaction was originally announced on December 29, 2025 and closed on July 1, 2026 following the satisfaction of all closing conditions. Under the ter...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Azenta
US1143401024

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Azenta
US1143401024

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Azenta
US1143401024

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026 -- then cut both targets three months later after recording a $149 million goodwill impairment.NEW YORK, May 27, 2026 /PRNewswire/ -- Shareholders who purchased Azenta, Inc. (NASDAQ: AZTA) stock lost significant value after the Company sl...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.05.2026       Azenta
US1143401024

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) ("Azenta, Inc.") concerning potential violations of the federal securities laws.On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for c...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Azenta
US1143401024

Law Offices of Howard G. Smith continues its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AZENTA, INC. (AZTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLA...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Azenta
US1143401024

The Law Offices of Frank R. Cruz continues its investigation of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Azenta
US1143401024

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQU...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 21.05.2026       Azenta
US1143401024

BURLINGTON, Mass., May 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued progress against its key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2025.The report offers a co...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Azenta
US1143401024

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2026       Azenta
US1143401024

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) ("Azenta, Inc.") concerning potential violations of the federal securities laws.On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positi...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.05.2026       Azenta
US1143401024

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Azenta
US1143401024

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA,...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Azenta
US1143401024

Law Offices of Howard G. Smith announces an investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AZENTA, INC. (AZTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAI...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Azenta
US1143401024

New York, New York--(Newsfile Corp. - May 13, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. ("Azenta, Inc.") (NASDAQ: AZTA) concerning potential violations of the federal securities laws.On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for c...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Azenta
US1143401024

Azenta, Inc. reported GAAP results revealing a $160.8 million net loss driven by a $149 million goodwill impairment. NEW YORK, May 13, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ: AZTA) investors lost money when the stock dropped sharply after the Company's Q2 FY 2026 earnings revealed a $160.8 million GAAP net loss -- largely driven by a non-cash...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Azenta
US1143401024

The Law Offices of Frank R. Cruz announces an investigation of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR L...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Sat, 09.05.2026       Azenta
US1143401024

The law firm of Kirby McInerney LLP is investigating potential claims against Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 05.05.2026       Azenta
US1143401024

FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 millionFY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growthFY'26 Adjusted EBITDA margin is now expected to range from down approximately 125 basis points to flat, compared...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       Azenta
US1143401024

BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 6, 2026, at 8:30...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Azenta
US1143401024

BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is a...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Azenta
US1143401024

BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relatio...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.02.2026       Azenta
US1143401024

BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.01.2026       Azenta
US1143401024

BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 202...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.12.2025       Azenta
US1143401024

BURLINGTON, Mass., Dec. 29, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA S.À R.L., for a purchase price of US$63 million. The transaction is expected to close on or before March 31, 2026."The ag...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Azenta
US1143401024

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation....
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Azenta
US1143401024

Q4'25 reported revenue growth of 6% year over year and 4% on an organic basisFY'25 reported revenue growth of 4% and 3% on an organic basisFY'25 Adjusted EBITDA margin expansion of 310 basis points versus last yearFY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis p...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Azenta
US1143401024

BURLINGTON, Mass., Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens. The Company will host a conference call and live webcast to discuss...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Azenta
US1143401024

BURLINGTON, Mass., Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative focused on early detection and prevention of pancreatic cancer. Azenta will provide secure storage of study samples i...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.10.2025       Azenta
US1143401024

BURLINGTON, Mass., Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility in Indianapolis, Indiana. This event will provide invited investors and analysts with a unique opportunity to gain...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Azenta
US1143401024

BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program....
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.07.2025       Azenta
US1143401024

BURLINGTON, Mass., July 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Tuesday, August 12, 2025. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worl...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.07.2025       Azenta
US1143401024

BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Azenta
US1143401024

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solu...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Azenta
US1143401024

BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intenti...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Azenta
US1143401024

BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.03.2025       Azenta
US1143401024

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fisc...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.03.2025       Azenta
US1143401024

BURLINGTON, Mass., March 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y. Lin, Executive Vice President and Chief Financial Officer, will participate in the Virtual KeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, 2025, which includes a presentation beginning at 10:30 am ET. The live webcast can be a...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.02.2025       Azenta
US1143401024

BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its int...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.01.2025       Azenta
US1143401024

BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier toda...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.01.2025       Azenta
US1143401024

BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 5, 20...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.01.2025       Azenta
US1143401024

BURLINGTON, Mass., Jan. 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of internationally significant sample collections. This new system is in addition to the seven Azenta BioAr...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.11.2024       Azenta
US1143401024

NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE: ENV) in the S&P SmallCap 600 effective prior to the opening...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       Azenta
US1143401024

BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT. The live webcast can be accessed through the Azenta investor relations website at htt...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Azenta
US1143401024

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and MultiomicsFY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsPursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitabilityAnn...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.11.2024       Azenta
US1143401024

BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, N...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.11.2024       Azenta
US1143401024

William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       Azenta
US1143401024

BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States.  Traditional short-read sequencing methods often st...
Read more
Azenta
Technical Analysis Termsheets Terminal
Permalink